| A Beta-only IL-2 ImmunoTherapY Study (NCT05086692) | Medicenna Therapeutics, Inc. | 2021-08-27 |
| A Study of DT2216 in Relapsed/Refractory Malignancies (NCT04886622) | Dialectic Therapeutics, Inc | 2021-08-25 |
| Efficacy and Safety of Duloxetine in Chinese Solid Tumor Patients with Taxanes-induced Painful Peripheral Neuropathy (NCT04970121) | Yan Yang, MD, Ph.D | 2021-08-21 |
| Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements (NCT05175235) | National University Hospital, Singapore | 2021-08-19 |
| A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma (NCT04970992) | Da Zen Theranostics Inc | 2021-08-12 |
| MAX-10181 in Patients With Advanced Solid Tumor (NCT05196360) | Maxinovel Pty., Ltd. | 2021-08-11 |
| Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors (NCT04780217) | ImmVira Pharma Co. Ltd | 2021-08-10 |
| 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression (NCT04927663) | Rahul Aggarwal | 2021-08-10 |
| ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors (NCT04891198) | 3D Medicines (Sichuan) Co., Ltd. | 2021-08-06 |
| Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 (NCT04787042) | Simcha IL-18, Inc. | 2021-08-06 |
| RAPA-201 Therapy of Solid Tumors (NCT05144698) | Rapa Therapeutics LLC | 2021-08-01 |
| LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors (NCT04690699) | Istari Oncology, Inc. | 2021-08-01 |
| A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (NCT04939610) | Novartis Pharmaceuticals | 2021-07-30 |
| A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China (NCT05009329) | Allist Pharmaceuticals, Inc. | 2021-07-26 |
| Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies (NCT04541108) | Presage Biosciences | 2021-07-26 |
| Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies (NCT05391022) | Constellation Pharmaceuticals | 2021-07-20 |
| A Bioequivalence Study to Compare Senaparib Manufactured at 2 Sites in Healthy Subjects in Fasting State (NCT07030439) | Impact Therapeutics, Inc. | 2021-07-18 |
| Pilot Trial of Eltrombopag in Patients Undergoing Chemotherapy for Malignant Solid Tumors (NCT04485416) | University of California, Davis | 2021-07-16 |
| Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors (NCT04985604) | Day One Biopharmaceuticals, Inc. | 2021-07-15 |
| A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin (NCT05357911) | Nuvation Bio Inc. | 2021-07-13 |
| GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor (NCT04944888) | Chinese PLA General Hospital | 2021-07-01 |
| Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors (NCT04900818) | I-Mab Biopharma US Limited | 2021-06-29 |
| Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values (NCT04942717) | Memorial Sloan Kettering Cancer Center | 2021-06-18 |
| Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors (NCT05103631) | Baylor College of Medicine | 2021-06-17 |
| GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies (NCT04937153) | Genmab | 2021-06-15 |
| A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody (NCT04866485) | Harbour BioMed (Guangzhou) Co. Ltd. | 2021-06-14 |
| PhI to Solid Tumors and PhII to Locally Advanced or mTNBC (NCT05390710) | Laekna Limited | 2021-06-12 |
| Dose Escalation Trial of BNT152+153 in Patients With Cancer (NCT04710043) | BioNTech SE | 2021-06-08 |
| Personalised Immunotherapy Platform (NCT06536257) | Melanoma Institute Australia | 2021-06-08 |
| Intestinal Microbiome Modification With Resistant Starch in Patients Treated With Dual Immune Checkpoint Inhibitors (NCT04552418) | University of Michigan Rogel Cancer Center | 2021-06-02 |
| Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion (NCT04617054) | Nuvation Bio Inc. | 2021-06-01 |
| A Study to Examine the Clinical Value of Comprehensive Genomic Profiling Performed by Belgian NGS Laboratories: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Centre (NCT05058937) | The Belgian Society of Medical Oncology | 2021-06-01 |
| A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors (NCT04903873) | Eutilex | 2021-05-31 |
| A Study of WX390 in Patients With Advanced Solid Tumors (NCT06117540) | Shanghai Jiatan Pharmatech Co., Ltd | 2021-05-11 |
| An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma (NCT04873440) | Chinese PLA General Hospital | 2021-05-06 |
| Clinical Study Comparing Different Strategies to Increase Adherence to Oral Therapies in Oncohematology (NCT04826458) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2021-05-04 |
| Clinical Study on PET Imaging, Distribution and PK of 89Zr-CD147 in Patients With Solid Tumors (NCT04841421) | Sinotau Pharmaceutical Group | 2021-05-01 |
| NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer (NCT04659629) | Neurogene Inc. | 2021-04-26 |
| Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor (NCT05278364) | Shouyao Holdings (Beijing) Co. LTD | 2021-04-23 |
| National Project on Vaccines, COVID-19 and Frail Patients (NCT04848493) | Azienda USL Reggio Emilia - IRCCS | 2021-04-19 |
| Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion (NCT04794699) | IDEAYA Biosciences | 2021-04-14 |
| A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors (NCT04794972) | Sichuan Baili Pharmaceutical Co., Ltd. | 2021-04-14 |
| Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma (NCT05221385) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2021-04-12 |
| Augsburg Longitudinal Plasma Study for the Evaluation of Liquid Biopsy as Diagnostic Tool. (NCT05245136) | University Hospital Augsburg | 2021-03-29 |
| Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases (NCT04832204) | Beijing Hospital | 2021-03-25 |
| Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors (NCT04931823) | Conjupro Biotherapeutics, Inc. | 2021-03-24 |
| JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors (NCT04720976) | Allist Pharmaceuticals, Inc. | 2021-03-23 |
| Local Radiotherapy in Combination With Immunotherapy in Advanced Solid Tumors Patients (NCT05097781) | Ruijin Hospital | 2021-03-21 |
| A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors (NCT04731467) | Famewave Ltd. | 2021-03-19 |
| PF-07284892 in Participants With Advanced Solid Tumors (NCT04800822) | Pfizer | 2021-03-17 |
| A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors (NCT04679038) | Jiangsu HengRui Medicine Co., Ltd. | 2021-03-17 |
| Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma (NCT04775680) | Adagene (Suzhou) Limited | 2021-03-11 |
| A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors (NCT04617314) | RemeGen Co., Ltd. | 2021-03-10 |
| TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor (NCT04862767) | Autotelicbio | 2021-03-09 |
| Pembrolizumab And Lenvatinib In Leptomeningeal Metastases (NCT04729348) | Massachusetts General Hospital | 2021-03-08 |
| TH1902 in Patients With Advanced Solid Tumors (NCT04706962) | Theratechnologies | 2021-03-04 |
| Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors (NCT04952272) | Second Affiliated Hospital of Guangzhou Medical University | 2021-03-01 |
| The Psychological Impact of COVID-19 on Patients with Solid Malignancies: a Single-Institution Survey Study (NCT05359718) | The Christie NHS Foundation Trust | 2021-03-01 |
| The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors (NCT04696848) | Tae Won Kim | 2021-02-24 |
| QUANTACT : Impact of Pangenomic QUANTitative Alterations in Cancer Therapy (NCT04762862) | Centre Hospitalier Universitaire de Nice | 2021-02-01 |
| Integrative Neuromuscular Training in Adolescents and Children Treated for Cancer (NCT04706676) | Rigshospitalet, Denmark | 2021-01-26 |
| BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors (NCT04455620) | BioNTech SE | 2021-01-26 |
| COVID-19 Vaccine Efficacy in Patients With Malignant Pathologies (NCT04776005) | Assistance Publique - Hôpitaux de Paris | 2021-01-22 |
| Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors (NCT04911907) | Beijing Biostar Pharmaceuticals Co., Ltd. | 2021-01-22 |
| TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy (NCT04695327) | TILT Biotherapeutics Ltd. | 2021-01-11 |
| Propofol vs Sevo for Paediatric Tumor Surgery (NCT04475705) | Hong Kong Children's Hospital | 2021-01-11 |
| Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System (NCT04743388) | National and Kapodistrian University of Athens | 2021-01-04 |
| First-in-Human Study of INT-1B3 in Patients With Advanced Solid Tumors (NCT04675996) | InteRNA | 2020-12-18 |
| Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors (NCT04678921) | I-Mab Biopharma US Limited | 2020-12-17 |
| LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors (NCT04666688) | PureTech | 2020-12-15 |
| Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors (NCT03740256) | Baylor College of Medicine | 2020-12-14 |
| A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors (NCT04452955) | Intra-IMMUSG Pte Ltd | 2020-12-12 |
| Interest of Medical Hypnosis in Anxious Patients Treated by Radiotherapy (NCT04513444) | Institut Claudius Regaud | 2020-12-07 |
| A Study of TY-302 in Patients With Advanced Solid Tumors (NCT04433494) | TYK Medicines, Inc | 2020-12-07 |
| Medical Treatment of Solid Tumors at the Lyon University Hospital Cancer Institute During the First Wave of COVID-19 in France: A Conservative Approach (NCT04910633) | Hospices Civils de Lyon | 2020-12-02 |
| LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers (NCT04665388) | University Health Network, Toronto | 2020-11-30 |
| Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies (NCT04672434) | Symphogen A/S | 2020-11-19 |
| Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor (NCT04648254) | Qurient Co., Ltd. | 2020-11-18 |
| Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy (NCT04393454) | Albert Einstein College of Medicine | 2020-11-16 |
| A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors (NCT04606472) | Sichuan Baili Pharmaceutical Co., Ltd. | 2020-11-10 |
| An Evaluation of Patients Access to Their Electronic Medical Records Via the IPC Connect Application (NCT04496375) | Institut Paoli-Calmettes | 2020-11-05 |
| IMP4297 DDI (Drug-Drug Interaction)Trial in Healthy Male Volunteers (NCT04584515) | Impact Therapeutics, Inc. | 2020-11-02 |
| αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors (NCT05373147) | Shanghai Mengchao Cancer Hospital | 2020-10-30 |
| BA Study of IMP4297 (20mg vs 10mg) in Healthy Male Subjects (NCT04351165) | Impact Therapeutics, Inc. | 2020-10-29 |
| A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects (NCT04508179) | 7 Hills Pharma, LLC | 2020-10-28 |
| GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy (NCT04601402) | Genome & Company | 2020-10-26 |
| A MolEcularly Guided Anti-Cancer Drug Off-Label Trial (NCT04185831) | Uppsala University Hospital | 2020-10-20 |
| Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies (NCT04641871) | Symphogen A/S | 2020-10-12 |
| Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors (NCT04588324) | Chinese PLA General Hospital | 2020-10-10 |
| A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors (NCT04419532) | Daiichi Sankyo | 2020-10-09 |
| NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors (NCT04550663) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2020-09-25 |
| Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers (NCT04553692) | IGM Biosciences, Inc. | 2020-09-23 |
| Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies (NCT04475523) | Curis, Inc. | 2020-09-22 |
| Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors (NCT04571632) | Universitair Ziekenhuis Brussel | 2020-09-22 |
| Phase I Clinical Study for Evaluation of Pharmacokinetic, Safety, Tolerance of Norcantharidin Lipid Microsphere for Injection in Patients With Solid Tumor (NCT04673396) | Beijing Nuokangda Pharmaceutical Technology Co., Ltd. | 2020-09-22 |
| Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer (NCT04557306) | CHABiotech CO., Ltd | 2020-09-21 |
| A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (NCT04370587) | ImmVira Pharma Co. Ltd | 2020-09-17 |
| Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies (NCT04552288) | Memorial Sloan Kettering Cancer Center | 2020-09-16 |
| Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors (NCT04469530) | Emory University | 2020-09-16 |
| A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors (NCT04503278) | BioNTech Cell & Gene Therapies GmbH | 2020-09-16 |